10:31 AM EDT, 08/06/2025 (MT Newswires) -- Crescita Therapeutics ( CRRTF ) up near 15% on last look, on Wednesday reported a swing to a second-quarter profit as revenue rose, while it is looking to expand its market presence, including discussions with potential partners for Pliaglis in Europe.

The skincare company reported net income of near $0.8 million, or $0.04 per basic and diluted share, compared with a loss of near $1 million, or $0.05 per share last year.

Total revenue rose to $6.2 million, from $4.1 million. The increase was primarily driven by the ramp-up of production volumes with a new customer in the Manufacturing segment.

Among other highlights, Adjusted EBITDA was also higher.

"We are pleased with the positive results for the quarter, which showed significant year-over-year improvement and strengthened our position as we enter the second half of 2025. Q2 was marked by the successful fulfillment of key purchase orders with a new manufacturing customer, and the continued growth in our Skincare segment," said Chief Executive Serge Verreault.

The CEO said while non-recurring in nature, the mutual termination agreement with Croma added approximately $900,000 to the topline and cash balance. When excluding its impact on results, the company achieved a breakeven Adjusted EBITA for the quarter.

"Looking ahead, we are optimistic about our growth prospects and are actively exploring strategic opportunities to further strengthen our position and expand our market presence, including discussions with potential partners for Pliaglis for certain available European countries," added Verreault.

The company's shares were last seen up $0.07, to $0.54, on the Toronto Stock Exchange.

Price: 0.54, Change: +0.07, Percent Change: +14.89